A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) (NCT05904886)
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Who can join: Review the eligibility criteria below.
Location: Genesis Cancer Center — Hot Springs, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (171 Sites)
Showing the first 25 of 171 sites.
- Genesis Cancer Center — Hot Springs, Arkansas
- UCSF Fresno at Community Cancer Institute — Clovis, California
- City of Hope Cancer Center — Duarte, California
- University of California San Diego Moores Cancer Center — La Jolla, California
- University of Southern California — Los Angeles, California
- Stanford Cancer Center — Palo Alto, California
- Va Palo Alto Health Care System — Palo Alto, California
- UCLA Cancer Center — Santa Monica, California
- Hartford Healthcare Cancer Institute at Hartford Hospital — Hartford, Connecticut
- MedStar Washington Hosp Center — Washington D.C., District of Columbia
- Florida Cancer Specialists - Fort Myers (Broadway) — Fort Myers, Florida
- Miami VA Healthcare System — Miami, Florida
- Florida Cancer Specialist, North Region — St. Petersburg, Florida
- University of Illinois — Chicago, Illinois
- Norton Cancer Institute - Audubon — Louisville, Kentucky
- Ochsner Cancer Inst. — New Orleans, Louisiana
- Mercy Medical Center — Baltimore, Maryland
- Henry Ford Health System — Detroit, Michigan
- Cancer & Hematology Centers of Western Michigan — Grand Rapids, Michigan
- Mayo Clinic Rochester — Rochester, Minnesota
- Minnesota Oncology Hematology Woodbury — Woodbury, Minnesota
- Washington Uni School of Medicine — St Louis, Missouri
- NYU Langone — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Columbia University — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma
- TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
- TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
- Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona
Explore by condition: All Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.